Ok Biotech Co Ltd (4155) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ok Biotech Co Ltd (4155) has a cash flow conversion efficiency ratio of 0.100x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$256.86 Million ≈ $8.09 Million USD) by net assets (NT$2.58 Billion ≈ $81.16 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ok Biotech Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Ok Biotech Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Ok Biotech Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ok Biotech Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ok Biotech Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TECO Image Systems Co Ltd
TWO:5438
|
-0.017x |
|
Gray Television Inc
NYSE:GTN-A
|
0.000x |
|
Loulis Mills S.A.
AT:KYLO
|
0.049x |
|
Engenco Ltd
AU:EGN
|
0.101x |
|
Golan Plastic
TA:GLPL
|
0.112x |
|
Ramssol Group Bhd
KLSE:0236
|
0.028x |
|
De Poan Pneumatic
TWO:1570
|
0.024x |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
0.013x |
Annual Cash Flow Conversion Efficiency for Ok Biotech Co Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of Ok Biotech Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Ok Biotech Co Ltd (4155) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$2.58 Billion ≈ $81.16 Million |
NT$319.57 Million ≈ $10.07 Million |
0.124x | +383.18% |
| 2024-12-31 | NT$2.57 Billion ≈ $80.87 Million |
NT$65.90 Million ≈ $2.08 Million |
0.026x | +1996.54% |
| 2023-12-31 | NT$2.40 Billion ≈ $75.46 Million |
NT$2.93 Million ≈ $92.41K |
0.001x | -99.06% |
| 2022-12-31 | NT$1.85 Billion ≈ $58.17 Million |
NT$240.53 Million ≈ $7.58 Million |
0.130x | +913.18% |
| 2021-12-31 | NT$1.70 Billion ≈ $53.65 Million |
NT$21.90 Million ≈ $689.84K |
0.013x | -84.86% |
| 2020-12-31 | NT$1.74 Billion ≈ $54.79 Million |
NT$147.70 Million ≈ $4.65 Million |
0.085x | +144.78% |
| 2019-12-31 | NT$1.30 Billion ≈ $41.02 Million |
NT$45.18 Million ≈ $1.42 Million |
0.035x | -65.83% |
| 2018-12-31 | NT$1.27 Billion ≈ $39.95 Million |
NT$128.75 Million ≈ $4.06 Million |
0.102x | +19.16% |
| 2017-12-31 | NT$1.21 Billion ≈ $38.00 Million |
NT$102.77 Million ≈ $3.24 Million |
0.085x | -69.12% |
| 2016-12-31 | NT$944.80 Million ≈ $29.77 Million |
NT$260.72 Million ≈ $8.21 Million |
0.276x | -9.41% |
| 2015-12-31 | NT$950.15 Million ≈ $29.94 Million |
NT$289.44 Million ≈ $9.12 Million |
0.305x | +864.81% |
| 2014-12-31 | NT$849.48 Million ≈ $26.76 Million |
NT$-33.83 Million ≈ $-1.07 Million |
-0.040x | -127.88% |
| 2013-12-31 | NT$609.65 Million ≈ $19.21 Million |
NT$87.08 Million ≈ $2.74 Million |
0.143x | -18.43% |
| 2012-12-31 | NT$452.10 Million ≈ $14.24 Million |
NT$79.17 Million ≈ $2.49 Million |
0.175x | -42.99% |
| 2011-12-31 | NT$303.11 Million ≈ $9.55 Million |
NT$93.12 Million ≈ $2.93 Million |
0.307x | +463.30% |
| 2010-12-31 | NT$230.78 Million ≈ $7.27 Million |
NT$-19.52 Million ≈ $-614.83K |
-0.085x | -247.52% |
| 2009-12-31 | NT$121.25 Million ≈ $3.82 Million |
NT$6.95 Million ≈ $218.96K |
0.057x | -- |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of blood glucose monitoring systems and homecare healthcare devices in Taiwan, the rest of Asia, America, Africa, and Europe. The company offers nebulizers, blood glucose meters, glucometers, blood sugar meters, and blood glucose test strips. It also provides OTC hearing aids, multi-f… Read more